HOW TO APPROACH THE PATIENT WITH LIFE-THREATENING BLEEDING

A Discussion on the Use of Blood Products and Other Interventions in Anticoagulant-Associated Bleeding, Disseminated Intravascular Coagulation, Hepatic Cirrhosis, and Intracranial Hemorrhage

Tiffany Reams, MHS, PA-C
Moffitt Cancer Center
Department of Malignant Hematology

OBJECTIVES

- Types of commonly used blood products
  - RBCs, platelets, fresh frozen plasma, cryoprecipitate
- Transfusion Reactions and Complications
  - Hemolytic, nonhemolytic, allergic, TRALI
- Anticoagulant Associated Bleeding
  - Warfarin, unfractionated and LMW heparins, DOACs
- Disseminated Intravascular Coagulation
  - Common etiologies, diagnosis, and treatment
- Bleeding in Hepatic Cirrhosis
  - Coagulopathies, esophageal varices
- Intracranial Hemorrhage
  - Common types and management

BLOOD PRODUCTS

- Packed Red Blood Cells (RBCs)
  - Whole Blood
  - Leukoreduction
  - Irradiation
- ABO/Rh Typing
- Adverse Effects
  - Hyperkalemia
  - Citrate Toxicity
- Platelets
  - Pooled
  - Cross-matched
  - HLA-matched

Photo from Wikipedia: "Transfusion Dependent Anemia" https://en.wikipedia.org/wiki/Transfusion-dependent_anemia

Photo from EMRN Medical Supplies,Inc. https://www.emrnmedicalsupplies.com/us/platelet-demo-bag-a-rh-pos.html

BLOOD PRODUCTS

- Fresh Frozen Plasma (FFP)
  - All coagulation factors
  - Weight based dosing
- Prothrombin Complex Concentrate (PCC)
  - Coag factors II, VII, IX, X
- Cryoprecipitate
  - Fibrinogen, fibronectin, factor VII, factor VIII, vWF
  - Commonly dosed as 10 unit bag



FRESH-FROZEN PLASMA (FFP) DOSAGE

Fresh-frozen plasma (FFP) has optimal value when transfused at the appropriate dose.
The **recommended adult therapeutic dose of FFP is 12-15 ml/kg** (1), and the dose of FFP should always be **at least 10 ml/kg** (2); however a recent report showed in clinical practice 40% of adults received a FFP dose <10 ml/kg (2).

The prescribed dose of FFP should be guided by clinical situation and coagulation results (1,3,4).

Calculations for one Adult Therapeutic Dose FFP

Patient Weight (kg)	FFP dose Volume / units †			
	12ml/kg	units FFP	15ml/kg	units FFP
Up to 60 kg	720 ml	3	900 ml	4
61 - 65 kg	780 ml	3	975 ml	4
66 - 70 kg	840 ml	3	1050 ml	4
71 - 75 kg	900 ml	4	1125 ml	4
76 - 80 kg	960 ml	4	1200 ml	5
81 - 85 kg	1020 ml	4	1275 ml	5
86 - 90 kg	1080 ml	4	1350 ml	5
91 - 95 kg	1140 ml	4	1425 ml	5
100+ kg	1200 ml	5	1500 ml	6

† Volume of FFP in a unit is variable, mean FFP unit volume ≈ 271 mls (1) (rounded up to 275 mls for ease of calculation)

Figure from FFP Dosage PDF. Joint United Kingdom Blood Transfusion and Tissue Transplantation Services Professional Advisory Committee <https://www.transfusionguidelines.org>

BLOOD TRANSFUSION REACTIONS

- Urticarial transfusion reaction (UTR)
  - Presents with hives, no other allergic symptoms
  - Antigen-antibody interaction
  - Treat with antihistamines (diphenhydramine, cetirizine, etc.)
- Allergic or anaphylactic reaction
  - Presents with angioedema, wheezing, hypotension
  - Occurs in IgA deficient individuals who produce anti-IgA antibodies that react with donor IgA in product or have allergies to other constituents in blood products
  - Treat with epinephrine, antihistamines, bronchodilators, or vasopressors if indicated

BLOOD TRANSFUSION REACTIONS

- Transfusion-associated circulatory overload (TACO)
  - Presents with acute shortness of breath, chest tightness, +/- hypoxia
  - Form of pulmonary edema due to volume excess or circulatory overload
  - CXR with interstitial pulmonary edema
  - Treat with diuretics, oxygen if needed
- Transfusion-related acute lung injury (TRALI)
  - Presents with fever, chills, tachycardia, hypotension, hypertension, respiratory distress/hypoxemia, transient leukopenia
  - Recipient neutrophils are activated by transfused product in pulmonary vasculature
  - Can occur with small volume of transfusion
  - Consult Pulm/Critical Care, support with oxygen, may require intubation/ventilation and notify Blood Bank



Figure 1: Chest X-ray after transfusion associated circulatory overload



Figure 2: Resolved transfusion associated circulatory overload

Adapted Image from Agnihotri, et al. Transfusion associated circulatory overload. Indian Journal of Critical Care Medicine. June 2014, Vol. 18; 6: 396-398

BLOOD TRANSFUSION REACTIONS

- Febrile hemolytic transfusion reaction
  - Presents with fever, chills, flank pain, oozing from IV sites – can lead to AKI, vasospasms, DIC
  - Down trending Hgb, positive DAT (Coombs test), low haptoglobin, elevated LDH and bilirubin, presence of Hgb in urine
  - Most common cause due to clerical error/mismatch of donor products to recipient profile
  - Treat with IVFs to minimize complications of free Hgb and notify BB
- Febrile nonhemolytic transfusion reaction
  - Presents with fever, chills without other systemic symptoms
  - Most common cause is cytokine release from WBCs in product that has not been leukoreduced, often diagnosis of exclusion
  - Treat with acetaminophen or antihistamines

Initial approach to a suspected acute transfusion reaction



These are some of the most common and life-threatening reactions; other reactions are also possible and should be pursued if the clinical picture seems inconsistent with one of these. The transfusion service should be notified of any severe transfusion reaction and

Figure from UpToDate, Inc. Initial approach to a suspected acute transfusion reaction. https://www.uptodate.com/contents/approach-to-the-patient-with-a-suspected-acute-transfusion -reaction

ANTICOAGULANT-ASSOCIATED BLEEDING

- Most common sites: GI tract (40%), Intracranial hemorrhage (25%), bladder, retroperitoneum, deep muscle
- Risk Factors: age (>75 yrs), metastatic cancer, immobility (>4 days), history of major bleed within 30 days, platelet count <100k, abnormal PT, CrCl<30
- Discuss reversal of commonly used anticoagulants (warfarin, unfractionated/LWM heparin, DOACs) and use of blood products to correct coagulopathy

ANTICOAGULANT-ASSOCIATED BLEEDING

- Warfarin
  - Acts by competitive inhibition of vitamin K epoxide reductase complex 1 (VKORC1), an enzyme that activates vitamin K in the body
  - Depletes functional vitamin K reserves thereby reducing synthesis of Vitamin K dependent clotting factors (factors II, VII, IX, X) as well as regulatory factors protein C and protein S



Figure from Paulus E, Komperda K, Park G, Fusco j. Anticoagulant therapy considerations in factor VII deficiency. Figure 1. Drug Safety – Case Reports. 2016 Aug 8.

ANTICOAGULANT-ASSOCIATED BLEEDING

- Warfarin
  - Risk of major bleeding associated with degree of anticoagulation (INR>5), Age >75 yrs, hepatic or renal disease, ethanol abuse, malignancy, reduced platelet count or function, uncontrolled hypertension, anemia, excessive fall risk, or increased risk of stroke
  - Major Bleeding
    - Hold warfarin, administer Vit K 10mg up to every 12hr until clinical improvement (or INR normalizes)
    - Can also use PCC (reverse within minutes of administration) or FFP as replacement of other Vitamin K dependent factors
  - Minor Bleeding
    - Hold warfarin, can give Vitamin K 2.5 – 5 mg, leads to correction within 24-48hr
  - Elevated INR without bleeding
    - Hold warfarin until INR falls within therapeutic range



Figure from Paulus E, Komperda K, Park G, Fusco j. Anticoagulant therapy considerations in factor VII deficiency. Figure 1. Drug Safety – Case Reports. 2016 Aug 8.

ANTICOAGULANT-ASSOCIATED BLEEDING

- Unfractionated heparin (UFH)
  - Acts by inhibiting factor Xa and also binds to antithrombin (AT) and coagulation enzyme to inhibit thrombin (factor II) production
  - Risk of bleeding
    - Associated with heparin dose, aPTT, patient factors (age >65yrs, female, peptic ulcer disease, malignancy, liver disease, recent surgery or trauma, concomitant use of other antithrombotic agents (ant-platelet agents or NSAIDs)



Figure from Paulus E, Komperda K, Park G, Fusco j. Anticoagulant therapy considerations in factor VII deficiency. Figure 1. Drug Safety – Case Reports. 2016 Aug 8.

ANTICOAGULANT-ASSOCIATED BLEEDING

- Major bleeding
  - Hold heparin, half-life ~1.5 hours
  - Reversal
    - Consider location/severity of bleeding, current aPTT, and underlying thromboembolic risk
    - Protamine sulfate
      - Dosage calculated on heparin dose and elapsed time since last use
      - If heparin given subQ, may need to repeat smaller dose of protamine due to prolonged heparin absorption
      - Black box warning: risk of anaphylaxis in patients with fish allergies or use of protamine-containing insulins
      - Adverse risks include hypotension, cardiovascular collapse, pulmonary vasoconstriction or pulmonary hypertension

Protamine Sulfate Dosage Recommendations

Time Elapsed From Last Heparin dose	Dose of Protamine (mg) to neutralize 100u of Heparin
Immediate	1.0 - 1.5 mg
30-60 minutes	0.5-0.75 mg
> 1 hour	0.25 – 0.375 mg

ANTICOAGULANT-ASSOCIATED BLEEDING

- Low Molecular Weight Heparin (LMWH)
  - Enoxaparin, dalteparin, tinzaparin, nadroparin
  - Half life ranges 3-7hrs, depends on normal renal function
  - Reversal depending on severity/location of bleed, anti-Xa activity (more accurate than aPTT)
    - Unlike in UFH, protamine sulfate does not completely abolish anti-Xa activity of LMWH (neutralizes 60-75%)

Protamine Sulfate Dosage Recommendations

LMWH	Half-Life	Protamine Sulfate Dose
enoxaparin	4.5 hours	<8 hrs: 1mg protamine per 1 mg enoxaparin >8hr: 0.5mg per 1 mg enoxaparin
dalteparin	2 hr (IV) 3-5 (SubQ)	1mg protamine per 100 anti-factor Xa units of LMWH
tinzaparin	4-5 hours	
nadroparin	3-4 hours	

ANTICOAGULANT-ASSOCIATED BLEEDING

- Direct thrombin inhibitors
  - Dabigatran, bivalirudin, argatroban
- Direct factor Xa inhibitors
  - Rivaroxaban, apixaban, edoxaban, betrixaban
- Longer half-lives, PT/aPTT/anti-Xa activity less helpful in quantifying anticoagulant effects



Figure from Paulus E, Komperda K, Park G, Fusco j. Anticoagulant therapy considerations in factor VII deficiency. Figure 1. Drug Safety – Case Reports. 2016 Aug 8.

ANTICOAGULANT-ASSOCIATED BLEEDING

- Major Bleeding
  - Discontinue anticoagulant
  - If recently ingested(<30 minutes) and low aspiration risk can consider activated charcoal
  - Consider reversal in setting of severe, life-threatening bleed – use clinical judgment regarding underlying thrombotic risk

Interval since last dose — We consider anticoagulation to have resolved **fully** after five half-lives have elapsed since the last dose. We use the following half-lives for patients with normal renal function [1]:

- Dabigatran - 12 to 17 hours; five half-lives will have elapsed by day 2.5 to 3.5 after the last dose.
- Rivaroxaban - 5 to 9 hours; five half-lives will have elapsed by day 1 to 2 after the last dose.
- Apixaban - 8 to 15 hours; five half-lives will have elapsed by day 1.5 to 3 after the last dose.
- Edoxaban - 6 to 11 hours; five half-lives will have elapsed by day 1.3 to 2 after the last dose.
- Betrixaban - 19 to 27 hours; five half-lives will have elapsed by day 4 to 5.5 after the last dose.

Excerpt from UpToDate, Inc. Management of bleeding in patients receiving direct oral anticoagulants. https://www.uptodate.com/contents/management-of-bleeding-in-patients-receiving-direct-oral-anticoagulants

ANTICOAGULANT-ASSOCIATED BLEEDING

- Reversal of dabigatran (if abnormal TT)
  - Idarucizumab – mAb fragment with higher binding affinity to dabigatran than thrombin acts as decoy
  - Can also consider hemodialysis (up to 50% reduction)
- Reversal of direct factor Xa inhibitors (rivaroxaban, apixaban, edoxaban)
  - Andexanet alfa – binds/sequesters factor Xa inhibitors, also increases TF pathway inhibitor increasing TF thrombin generation
    - Boxed Warning: associated with arterial and venous thromboembolic events, ischemic events, cardiac arrest, sudden death



Figure from Ciechanski et al. The new way of dabigtran reversal – idarucizumab. Journal of Education, health, and Sport. 2019; 9(2) 108-112



Figure from Sartori M, Cosmi B. Andexanet alfa to reverse the anticoagulant activity of factor Xa inhibitors: a review of design, development, and potential place in therapy. Journal of Thrombosis and Thrombolysis. 2018: 45

DISSEMINATED INTRAVASCULAR COAGULATION

- Acute type (uncompensated)
  - Increased expression of tissue factor (TF) on circulating monocytes and endothelial cells leads to overwhelming thrombin and fibrin generation
  - Deposition of fibrin in vasculature coupled with impaired fibrinolysis leads to thrombosis and organ damage
  - Increased presence of thrombin activates plts and circulating coag factors to overwhelm marrow and liver synthesis ultimately resulting in thrombocytopenia, factor depletion, and hypofibrinogenemia
  - Initially a procoagulant process that leads to a consumptive coagulopathy
- Common causes
  - Infection (bacterial, fungal, viral, parasitic, endotoxins), malignancy (APL, AML, ALL, pancreatic, ovarian, or brain tumors), severe burns, pregnancy complications, intravascular hemolysis (i.e. FHTR)



Figure 1. Mechanisms leading to the development of DIC. *FDP* = fibrin degradation products. (Adapted from Gobel BH. Disseminated intravascular coagulation in cancer: providing quality care. *Topics Adv Pract Nurs J* [online] 2002;2(4). Accessed October 2008

DISSEMINATED INTRAVASCULAR COAGULATION

- Chronic type (compensated)
  - Continuous or intermittent exposure to small amounts of TF or other procoagulant substances
  - Factors and plts are consumed but production is able to compensated with hepatocyte production of new factors and ability to clear fibrin degradation products
  - Thrombosis generally predominates bleeding, although most patients are asymptomatic
- Common causes
  - Advanced/metastatic cancers especially with CNS involvement



Figure 1. Mechanisms leading to the development of DIC. *FDP* = fibrin degradation products. (Adapted from Gobel BH. Disseminated intravascular coagulation in cancer: providing quality care. *Topics Adv Pract Nurs J* [online] 2002;2(4). Accessed October 2008

DISSEMINATED INTRAVASCULAR COAGULATION

- Acute type presents with mucosal bleeding (gums or GI tract), oozing around peripheral or central lines, bruising, hematomas, thromboembolism
- Severe cases can lead to organ damage: hepatic or renal failure, intracranial hemorrhage, respiratory failure (DAH), shock
- Diagnostic work-up
  - Labs, imaging

Coagulation parameters in acute and chronic disseminated intravascular coagulation

Parameter	Acute (decompensated) DIC	Chronic (compensated) DIC
Platelet count	Reduced	Variable
Prothrombin time (PT)	Prolonged	Normal
Activated partial thromboplastin time (aPTT)	Prolonged	Normal
Thrombin time	Prolonged	Normal to slightly prolonged
Plasma fibrinogen	Reduced	Normal to elevated
Plasma factor V	Reduced	Normal
Plasma factor VIII	Reduced	Normal
Fibrin degradation products	Elevated	Elevated
D-dimer	Elevated	Elevated

In chronic DIC, the thrombin time is more sensitive than PT or aPTT to the effects of increased D-dimer and fibrin degradation products.

DIC: disseminated intravascular coagulation.

Table from UpToDate, Inc. Disseminated intravascular coagulation (DIC) in adults: Evaluation and management. https://www.uptodate.com/contents/disseminated-intravascular-coagulation-dic-in-adults-evaluation-and-management

DISSEMINATED INTRAVASCULAR COAGULATION

- Treatment
  - Target underlying process: antibiotics for septic bacteremia, chemotherapy for malignancy, etc.
  - If bleeding:
    - Support hemostasis through transfusions (RBCs, Plts, Cryo, FFP)
    - Plts>50k, if elevated PT or aPTT give FFP, if fibrinogen <100 give cryoprecipitate
    - Avoid use of antifibrinolytics (tranexamic acid or PCC) can increase risk of thrombotic complications
    - Trend CBC, PT, PTT, fibrinogen closely
  - Prognosis: typically resolves within a few days after trigger event is controlled or removed

DISSEMINATED INTRAVASCULAR COAGULATION

- Acute Promyelocytic Leukemia (APL)
  - Leukemia characterized by atypical promyelocytes in bone marrow and peripheral circulation
  - Rearranged RARA gene in APL activates TF promotion and increases its expression in leukemic cells
  - TF expression upregulated by cells undergoing apoptosis
  - Death of APL cells also releases extracellular chromatin and phosphatidylserine increases thrombin generation and fibrin formulation
- Bleeding and abnormal coagulopathy either present at diagnosis or shortly after initiation of chemotherapy
- Monitor CBC, Coags, PT, aPTT, fibrinogen closely
- Transfuse plts>50k, fibrinogen >100k (if bleeding) or >150k
- Treat with ATRA (all trans-retinoic acid), arsenic trioxide, or gemtuzumab ozogamicin in high risk APL



Image from Gordon, SW, Geoffrey KW. Auer rods. Images in Clinical Medicine. N Engl J Med 2017; 376:2065

BLEEDING IN HEPATIC CIRRHOSIS

- End result of hepatocellular injury that leads to fibrosis and regenerative nodules in liver
- Common causes include chronic viral hepatitis, ethanol use, drug toxicity, autoimmune disorders, or metabolic liver disease (NAFLD)
- Bleeding complications often result from
  - Variceal bleeding (esophageal or gastric veins)
  - Thrombocytopenia, Coagulopathies, Hyperfibrinolysis
    - Thrombocytopenia – decreased hepatic synthesis of thrombopoietin, alcoholic marrow suppression, folate deficiency, splenic sequestration, or concurrent sepsis
    - Hepatocyte site of production for almost all numbered coag factors including fibrinogen, thrombin, V, VII, IX, X, and XI. Vitamin K deficiency also affects dependent factors prothrombin, VII, IX, and X
    - Difficult to correlate bleeding risk with aPTT as bleeding cases also have component of increased fibrinolysis due to changes in fibrinogen structure
      - Increased levels of tissue plasminogen activator (tPA), decreased levels of thrombin-activated fibrinolysis inhibitors, fibrinolytic activity of ascitic fluid delivered to systemic circulation via thoracic duct

BLEEDING IN HEPATIC CIRRHOSIS

- Esophageal and gastric variceal bleeding
  - Often presents with bright red blood, coffee ground emesis, or melena
  - Physiology
  - Treatment
    - Stabilize first – fluids, transfusions (Hgb<7, Plt>50k, optimize INR and fibrinogen levels if abnormal, use of cryo>FFP), strict I/O monitoring
    - Airway protection (especially if hematemesis present)
    - GI consult – typically repair via endoscopic band/ligation, sclerotherapy, TIPS procedure in severe/life-threatening scenario
    - Supportive therapy with pantoprazole IV (if concern for PUD/gastritis), octreotide (reduces splanchnic and portal blood flow), prophylactic antibiotics (ceftriaxone, ciprofloxacin, consider ID consult)



Figure from Cleveland Clinic Health Library: Esophageal Varices. https://my.clevelandclinic.org/health/diseases/15429-esophageal-varices.

BLEEDING IN HEPATIC CIRRHOSIS

- Accelerated intravascular coagulation and fibrinolysis (AICF)
  - Similar to DIC, however deficit in synthesis of procoagulant and anticoagulant factors occur due to impaired hepatocyte production rather than consumption from overactive thrombin generation
  - Occurs in 5-10% decompensated cirrhosis cases
  - Presents as intractable, delayed bleeding from surgical/dental interventions or spontaneous bleeding without recognizable trauma
  - Prolonged PT, INR, and aPTT. Mild thrombocytopenia, elevated D-dimer, low fibrinogen
  - Support with transfusions (RBCs, Plts, Cryo, FFP) and/or vitamin K supplementation



Figure from UpToDate, INC. Cirrhosis in adults: Overview of complications, general management, and prognosis. https://www.uptodate.com/contents/cirrhosis-in-adults-overview-of-complications-general-management-and-prognosis

INTRACRANIAL HEMORRHAGE

- Results from rupture of a vessel anywhere within the cranial cavity
- Classified by location (intraparenchymal, intraventricular, subarachnoid, subdural, epidural), nature of ruptured vessel (arterial, capillary, venous), and cause (primary, secondary)
- Common causes: trauma, arteriovenous malformations, aneurysms, tumors, abscesses, angiomas, drug use, anticoagulant therapy, bleeding disorders (benign, malignant, DIC)

	Intraparenchymal	Intraventricular	Subarachnoid	Subdural	Epidural
Location	Inside of the brain	Inside of the ventricle	Between the arachnoid and the pia mater	Between the Dura and the arachnoid	Between the dura and the skull
Imaging					
Mechanism	High blood pressure, trauma, arteriovenous malformation, tumor, etc	Can be associated with both intraparenchymal and subarachnoid hemorrhages	Rupture of aneurysms or arteriovenous malformations or trauma	Trauma	Trauma or after surgery
Source	Arterial or venous	Arterial or venous	Predominantly arterial	Venous (bridging veins)	Arterial
Shape	Typically rounded	Conforms to ventricular shape	Tracks along the sulci and fissures	Crescent	Lentiform
Presentation	Acute (sudden onset of headache, nausea, vomiting)	Acute (sudden onset of headache, nausea, vomiting)	Acute (worst headache of life)	May be insidious (worsening headache)	Acute (skull fracture and altered mental status)

Figure and images from Radiological Society of North America. RSNA Intracranial hemorrhage and its subtypes. https://www.kaggle.com/c/rsna-intracranial-hemorrhage-detection/overview/hemorrhage-types

INTRACRANIAL HEMORRHAGE

- Presents with headache (most common for subarachnoid type), dizziness, unilateral visual changes, altered mental status, slurred speech, nausea, vomiting, extremity weakness
- Assess cranial nerves and neurological exam
- CT head w/o contrast, MRI has higher sensitivity for blood products
- Consult Neurosurgery and Critical Care (Transfer to ICU)
  - Discontinue all anticoagulant and antiplatelet therapy. Consider reversal of anticoagulants if appropriate
  - Correct thrombocytopenia (Plt>100k), coagulopathies (optimize INR, fibrinogen levels)
  - Tight BP control: if SBP 150-220 lower to target SBP 140
    - Avoid nitroprusside or nitroglycerin – can increase intracranial pressure
  - Serial neuro exams, HOB 30 deg, antipyretics if T>38 deg C, monitor Na level keep>135, anti-seizure prophylaxis
  - NRSY/Critical Care may recommend use of osmotic therapy (hypertonic saline or mannitol) or therapeutic hyperventilation to treat increased ICP. Select patients may benefit from surgical decompression or evacuation of hematomas
  - LPs often contraindicated with ICH due to concern for tonsillar herniation and midbrain compression
- Prognosis dependent on location/severity of bleed, rate of resolution, secondary complications (seizures, respiratory depression, immobility)

SOURCES

Blood Products/Reactions

Carson JL, Grossman, BJ, et al. Red blood cell transfusion: a clinical practice guideline from the AABB. Ann Intern Med. 2012; 157 (1):49

Kaufman, Djulbegovic. Platelet transfusion: a clinical practice guideline from the AABB. Ann Intern Med. 2015 Feb 3. https://www.acpjournals.org/doi/pdf/10.7326/M14-1589

Vamvakas, EC, Blajchman MA. Transfusion-related mortality: the ongoing risks of allogenic blood transfusion and the available strategies for their prevention. Blood. 2009; 113:3406.

Toy, P. TRALI – Definition, mechanisms, incidence, and clinical relevance. Best Pract Res Clin Anaesthesiol. 2007 Jan 6; 21 (2): 183-193

Skeate RC, Estlund T. Distinguishing between transfusion related lung injury and transfusion associated circulatory overload. Curr Opin Hematol 2007; 14:682

Andreoli, TE, Cecil RL. Cecil's essentials of medicine: 9th Edition: "Disorders of Hemostasis: Bleeding" Elsevier Saunders 2016. pp. 544-563

Anticoagulant-associated Bleeding

Nieto JA, et al. Fatal bleeding in patients receiving anticoagulant therapy for venous thromboembolism. Journal of Thrombosis and Haemostasis. 2010 Jun 7; 8 (6), 1216-1222

Kuijer PM, Hutten BA, Prins MH, Buller HR. Prediction of the risk of bleeding during anticoagulant treatment for venous thromboembolism. Arch Intern Med. 1999; 159:457

Crowther MA, Ageno W, Garcia D, et al. Oral vitamin K versus placebo to correct excessive anticoagulation in patients receiving warfarin: a randomized trial. Ann Intern Med 2009; 150:293

Cook, B. Anticoagulation management. Semin Intervent Radiol. 2010 Dec; 27 (4): 360-367

Garcia DA, Balin TP, Weitz jI, et al. Parenteral anticoagulants: Antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012; 141.

Sartori M, Cosmi B. Andexanet alfa to reverse the anticoagulant activity of factor Xa inhibitors: a review of design, development, and potential place in therapy. Journal of Thrombosis and Thrombolysis. 2018: 45

Disseminated Intravascular Coagulation (DIC)

Levi M, Toh, CH, Thachil J, Watson HG. Guidelines for the diagnosis and management of disseminated intravascular coagulation. British Committee for Standards in Haematology. Br J Haematol 2009; 145:24

Siegal T, Seligsohn U, Aghai E, et al. Clinical and laboratory aspects of disseminated intravascular coagulation (DIC): a study of 118 cases. Thromb Haemost 1978; 39:122

SOURCES

Disseminated Intravascular Coagulation (Continued)

Squizzato A, Hunt BJ, Kinasewitz GT, et al. Supportive management strategies for disseminated intravascular coagulation. An international consensus. Thromb Haemost 2016; 115: 896.

Kitchens CS. Thrombocytopenia and thrombosis in disseminated intravascular coagulation (DIC). Hematology Am Soc Hematol Educ Program 2009; 240.

Tallman MS, Kwaan HC. Reassessing the hemostatic disorder associated with acute promyelocytic leukemia. Blood 1992; 79:543.

Bleeding in Cirrhosis

Tripodi A, Mannucci PM. The coagulopathy of chronic liver disease. N Engl J Med. 2011; 365 (2): 147

Northup PG, Garcia-Pagan JC, et al. Vascular liver disorders, portal vein thrombosis, and procedural bleeding in patients with liver disease: 2020 practice guidance by the American Association for the Study of Liver Diseases

Qamar, AA, Grace ND, Groszmann RJ, et al. Incidence, prevalence, and clinical significance of abnormal hematologic indices in compensated cirrhosis. Clin Gastroenterol Hepatol. 2009 Jun; 7(6): 689-95.

Intracranial Hemorrhage

Andreoli, TE, Cecil RL. Cecil's essentials of medicine: 9th Edition: "Disorders of Hemostasis: Bleeding" Elsevier Saunders 2016. pp. 1036-1037

Hemphill JC, Greenberg SM, Et al. Guidelines for the management of spontaneous intracerebral hemorrhage: A guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2015 Jul; 46 (7): 2032-60.